Entrada Therapeutics Engages Investors at Key Conferences
BOSTON, Entrada Therapeutics, Inc. (Nasdaq: TRDA) is excited to announce its participation in two significant upcoming investor conferences that will highlight the innovative work the Company is doing.
Jefferies Global Healthcare Conference
Dipal Doshi, the Chief Executive Officer of Entrada Therapeutics, will present at the Jefferies Global Healthcare Conference in London. This event will take place on a Tuesday, allowing attendees to gain insights into the Company's latest developments aimed at revolutionizing treatment approaches.
Fireside Chat at Evercore Healthcare Conference
In addition to the presentation, Doshi will also take part in a fireside chat at the 8th Annual Evercore Healthcare Conference. Scheduled for a Wednesday afternoon, this discussion will delve deeper into the Company's mission and vision, potentially unveiling future plans for innovation and growth.
Live Webcasts and Replays
For those interested in attending virtually, live webcasts of the presentations and discussions will be available on the Investor Relations section of Entrada’s website. These sessions promise to be informative, providing a unique glimpse into the promising developments within the Company. Replays will also be accessible for a duration of 90 days, ensuring that all interested stakeholders can catch up on the information presented.
About Entrada Therapeutics
Entrada Therapeutics is a pioneering clinical-stage biopharmaceutical company dedicated to enhancing patient lives through innovative medicines. It focuses on a new class of therapeutics that specifically engage intracellular targets previously deemed inaccessible. The proprietary Endosomal Escape Vehicle (EEV™) technology allows effective intracellular delivery of a diverse range of therapies into various tissues and organs, significantly improving therapeutic efficacy.
Advancing Development Portfolio
The Company is making remarkable strides in developing its portfolio, which includes numerous RNA- and protein-based programs targeting conditions such as neuromuscular and ocular diseases. Entrada’s lead programs focus on transforming treatments for individuals with Duchenne Muscular Dystrophy who are amenable to exon skipping at specific sites, including exons 44, 45, 50, and 51.
Collaborative Efforts in Research
Furthermore, Entrada has engaged in partnerships to nurture advanced clinical-stage programs. One notable collaboration includes the development of VX-670 aimed at myotonic dystrophy type 1, underscoring the Company’s commitment to addressing complex diseases through innovative solutions.
Contact Information
For more detailed information about Entrada Therapeutics and its groundbreaking efforts, please visit their official website. For investor inquiries, Karla MacDonald, the Chief Corporate Affairs Officer, can be contacted via email for detailed discussions about the Company’s vision and future projects.
Frequently Asked Questions
What is Entrada Therapeutics?
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat serious diseases.
Which conferences will Entrada Therapeutics participate in?
Entrada Therapeutics will participate in the Jefferies Global Healthcare Conference and the Annual Evercore Healthcare Conference.
Who will be representing the company?
Dipal Doshi, the Chief Executive Officer, will represent Entrada Therapeutics at both conferences.
How can I access the conference presentations?
Live webcasts will be available on the Company’s Investor Relations website during the conferences.
What is the focus of Entrada Therapeutics' research?
The research focuses on engaging intracellular targets and developing treatments for neuromuscular and ocular diseases.
